TrialBlood2014

Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.

Paul M Barr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.